FloridaTaper

Category: BIND

Benzodiazepine-Induced Neurological Dysfunction: mechanism, course, and recovery.

  • Dysautonomia After Long-Term Benzodiazepine Use: What Autonomic Function Testing Can and Cannot Show

    Dysautonomia After Long-Term Benzodiazepine Use: What Autonomic Function Testing Can and Cannot Show

    Patients with autonomic symptoms after long-term benzodiazepine use (orthostatic intolerance, palpitations, temperature dysregulation, gastrointestinal dysmotility, urinary dysfunction, sweating abnormalities) are sometimes referred for formal autonomic function testing (AFT) to objectively characterize the problem. The results often do not match the intensity of the clinical picture. Patients who feel substantially disabled by autonomic symptoms frequently receive reports showing “mild” or “minimal” abnormalities, or even findings within the normal range on most parameters. This mismatch is a source of frustration for patients and, for some clinicians, becomes evidence that the symptoms are not as real as the patient believes. Neither interpretation is quite right, and understanding what AFT can and cannot detect explains the mismatch. If you have been handed one of those “mild” reports, this is written for you.

    What AFT Actually Measures

    Autonomic function testing is a panel of studies assessing different components of autonomic control. A typical full evaluation includes several elements.

    Tilt-table testing. Assesses heart rate and blood pressure response to passive head-up tilt. Identifies orthostatic hypotension (a sustained drop in blood pressure on standing), postural tachycardia syndrome (POTS, a sustained heart rate increase of 30 beats per minute or more within ten minutes of standing, without orthostatic hypotension), and neurocardiogenic syncope. A higher heart rate threshold applies to adolescents.

    Heart rate variability with deep breathing. Measures the cardiovagal response, the expected heart rate acceleration on inhalation and deceleration on exhalation. Reduced variability indicates impaired parasympathetic control.

    Valsalva maneuver. Assesses both sympathetic and parasympathetic responses through the stereotyped blood pressure and heart rate changes during and after forced exhalation against a closed glottis.

    Quantitative sudomotor axon reflex test (QSART). Measures sweat response at defined skin sites to assess postganglionic sympathetic sudomotor function. Abnormal in length-dependent autonomic neuropathies and in some focal neuropathies.

    Thermoregulatory sweat test (TST). Whole-body sweat response to controlled heat challenge; a broader assessment of sweating patterns.

    Supine and standing catecholamines. Useful in POTS evaluation and in distinguishing hyperadrenergic from other forms.

    The panel is designed to characterize autonomic function systematically and to identify specific patterns suggesting particular diagnoses: pure autonomic failure, multiple system atrophy, diabetic autonomic neuropathy, POTS, various peripheral autonomic neuropathies.

    What AFT Shows in Benzodiazepine-Related Dysautonomia

    Several patterns turn up often.

    POTS-type findings. A subset of patients with benzodiazepine withdrawal-related autonomic symptoms, in clinical experience, meet diagnostic criteria for POTS on tilt-table testing, with heart rate increases of 30 beats per minute or more within ten minutes of standing in the absence of significant orthostatic hypotension.

    Reduced heart rate variability. Parasympathetic dysfunction with reduced heart rate variability and blunted deep-breathing responses is frequently documented.

    Hyperadrenergic features. Elevated standing norepinephrine, exaggerated blood pressure lability, and excessive heart rate response to minimal stimuli are seen often.

    Normal or near-normal QSART and TST. The sudomotor system is typically not abnormal on these tests in withdrawal-related dysautonomia, in contrast to structural peripheral autonomic neuropathies where these are often abnormal.

    Normal structural workup. Paraneoplastic panels, ganglionic acetylcholine receptor antibodies, and other antibody studies are typically negative.

    Taken together, the pattern is functional autonomic dysfunction, predominantly in the hyperadrenergic or mixed direction, without the structural peripheral nerve involvement of conditions such as diabetic autonomic neuropathy or immune-mediated autonomic neuropathy.

    What AFT Does Not Show

    Several features of the clinical picture are real but are not captured well by standard AFT. If your report reads as mild, one or more of these is usually the reason.

    Temporal variability. A patient whose autonomic symptoms fluctuate substantially across days or weeks may be tested on a relatively good day, producing results that under-represent the typical burden.

    Symptom severity. A patient with modest objective findings can still be substantially disabled by the subjective experience of autonomic symptoms. The tests measure physiologic parameters, not symptom burden, and the correlation is imperfect.

    Central autonomic dysregulation. Much of the dysautonomia in benzodiazepine withdrawal is driven by central, supraspinal dysregulation rather than peripheral autonomic damage. Tests designed to identify structural peripheral deficits may look relatively normal even when central autonomic control is substantially impaired.

    Episodic autonomic phenomena. Episodes of flushing, hot flashes, palpitations, or gastrointestinal phenomena may be completely absent during the testing period and therefore not captured.

    Mast cell and neuroimmune contributions. In a subset of patients the autonomic picture may have contributions from mast cell activation and neuroinflammation. Evidence here is limited, and AFT does not assess it directly.

    The underlying limitation is that AFT was developed to characterize specific structural autonomic diseases and related conditions. Functional autonomic dysregulation from a pharmacologic withdrawal syndrome is recognizable on some components of the test panel but is not the condition the tests were designed for.

    What a Positive AFT Is Good For

    If your testing does document an abnormality, that documentation serves several purposes.

    Establishing that the symptoms have a physiologic correlate. For patients who have been dismissed or assessed as having purely psychological symptoms, a tilt-table confirming POTS or a documented reduction in heart rate variability provides an anchor that redirects the clinical conversation. It also anchors a point that is easy to lose in that conversation: physical dependence on a prescribed benzodiazepine is not addiction, and the autonomic dysfunction that can follow long-term use and withdrawal is a medical condition with measurable physiology, not a personality trait.

    Supporting disability and insurance processes. Documentation of measurable dysautonomia has practical value in employment accommodation, disability claims, and insurance coverage of related treatments.

    Guiding specific therapy. A documented POTS pattern points toward management specific to that pattern, which your doctor can discuss. Documented orthostatic hypotension points toward management specific to that. Without documentation, the selection of autonomic-directed therapy is more speculative.

    Excluding structural disease. Normal QSART and normal antibody panels reduce the prior for immune-mediated autonomic neuropathy or paraneoplastic conditions that would require different treatment.

    What a Negative AFT Does and Does Not Mean

    A largely normal AFT result does not take your symptoms away. It means three things.

    Structural autonomic disease is unlikely. Peripheral autonomic neuropathies and the identifiable structural causes of dysautonomia are not driving the picture.

    Functional dysautonomia is not excluded. Central autonomic dysregulation, fluctuating peripheral function, and episodic phenomena are not reliably captured by a single testing session.

    Management follows from the clinical picture rather than the test. A clinician who dismisses symptoms on the basis of a normal AFT is working from a framework in which only identifiable structural disease counts, which is not how functional autonomic dysfunction operates.

    One caution stands apart from all of this. Fainting, chest pain, palpitations with breathlessness, or a new neurological symptom is not something to attribute to withdrawal and wait out, whatever the testing said: call 911 or seek emergency care if the symptom is severe, and get same-day evaluation otherwise.

    What to Ask For

    If you are considering AFT in the context of benzodiazepine withdrawal, several practical requests matter.

    Schedule the test during a period of typical symptom burden rather than an unusually good window. Testing when symptoms are mild produces results that do not reflect the usual clinical state.

    Ensure the panel includes tilt-table with catecholamines and heart rate variability assessment. These are the components most likely to produce relevant positive findings in this population.

    Request that the report include specific numeric values, not only categorical interpretations. A heart rate increase of 28 beats per minute on standing, just under the POTS threshold, is clinically meaningful even if it does not meet criteria. Raw values allow nuanced clinical interpretation.

    Discuss the results in the context of the benzodiazepine history. An autonomic specialist unfamiliar with benzodiazepine-related dysautonomia may interpret findings in isolation; a review that places results in the withdrawal context produces more useful conclusions.

    The Underlying Point

    Autonomic function testing is useful for characterizing dysautonomia after long-term benzodiazepine use, particularly when it documents POTS or related patterns that justify specific management. It is not a definitive test. A normal result does not establish that the symptoms are not autonomic in origin; it establishes that the specific patterns the test was designed to detect are not prominent. The clinical picture remains the primary data source; AFT supplements it without replacing it, and the combined information is what should drive management.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • When a Neurologist Orders an MS Workup for a Patient With BIND: What the Differential Should Include

    When a Neurologist Orders an MS Workup for a Patient With BIND: What the Differential Should Include

    A patient with paresthesias, tremor, fatigue, cognitive dysfunction, and sensory disturbances arriving at a neurology clinic will often leave with an order for a multiple sclerosis (MS) workup. The reasoning is straightforward: the symptom list triggers the MS differential, and a prudent neurologist wants to exclude a treatable and progressive neurological disease before settling on less specific explanations. For patients with benzodiazepine-induced neurological dysfunction (BIND), this is usually the right clinical instinct to follow, since MS can occur in patients who happen to have a benzodiazepine history, and its exclusion is genuinely useful. What often goes wrong is what happens after the MS workup returns negative, and what the rest of the differential should have included alongside MS from the beginning.

    Why the MS Differential Gets Triggered

    Several features of BIND present as neurological symptoms that a neurologist examining the patient for the first time could reasonably read as MS.

    Paresthesias and dysesthesias are the most common trigger. Tingling, numbness, burning sensations, and altered tactile perception can appear in various distributions. MS classically produces patchy, asymmetric sensory changes corresponding to demyelinating lesions, while BIND produces more diffuse, bilateral sensory symptoms, but the distinction is not always clean at presentation. Both conditions also produce substantial fatigue that is out of proportion to activity.

    Cognitive dysfunction overlaps as well. MS can produce slowed processing speed, attention difficulties, and executive dysfunction, and BIND produces similar cognitive features, so a neurologist evaluating the cognitive complaint alone may consider MS reasonably. Visual symptoms overlap too. Blurred vision, floaters, and altered visual perception occur in both. Optic neuritis is a defining MS event; BIND does not produce optic neuritis but can produce visual symptoms that prompt an evaluation for it.

    Tremor is common in BIND and can also appear in MS. Ataxia and coordination difficulties are less common in BIND than in MS but can occur, and both conditions can affect balance and gait. Autonomic features overlap as well: MS can involve urinary urgency, bowel changes, and sexual dysfunction, while BIND frequently involves broader autonomic dysfunction.

    One caution belongs here, because overlap is not sameness. Sudden loss of vision in one eye, new weakness or numbness confined to one side of the body, trouble speaking, or a first seizure are not symptoms to wait out as withdrawal; they need emergency care the same day, so call emergency services if they appear.

    What the MS Workup Typically Shows

    The standard MS workup includes magnetic resonance imaging (MRI) of the brain and cervical spine with and without contrast, evaluation of cerebrospinal fluid (CSF) for oligoclonal bands and the immunoglobulin G (IgG) index, and often evoked potentials. Supportive laboratory evaluation typically includes vitamin B12, thyroid function, and other mimics.

    There is no BIND-specific imaging or spinal fluid literature to point to, so what follows is clinical experience rather than a published series. In Dr. Leeds’ experience, and in what patients in the BIND community consistently report, the structural workup comes back normal.

    MRI is usually unremarkable. There are no demyelinating lesions in the periventricular, juxtacortical, infratentorial, or spinal cord distributions that MS diagnostic criteria require, and brain parenchyma appears normal or shows age-appropriate changes.

    CSF is usually negative for oligoclonal bands not present in serum, the IgG index is not elevated, and CSF cell counts and protein are unremarkable. Evoked potentials, when performed, tend to be normal or non-specific.

    The workup essentially excludes MS.

    What Should Be Part of the Differential Alongside MS

    A neurologist evaluating the same symptom picture should ideally consider several additional diagnoses from the start, not only after MS has been excluded.

    BIND itself belongs on the list. In a patient with long-term benzodiazepine exposure and a recent taper or discontinuation, BIND is a specific diagnostic candidate supported by an established clinical framework. The clinical features, which are time-locked to benzodiazepine changes, accompanied by autonomic and sensory hypersensitivity, and fluctuating in the waves-and-windows pattern, are recognizable.

    Vitamin B12 deficiency produces peripheral neuropathy, paresthesias, ataxia, and cognitive symptoms. Serum B12 with methylmalonic acid and homocysteine for borderline values is appropriate. Severely low vitamin D has been associated with neurologic symptoms and is cheap to exclude. Both hyperthyroidism and hypothyroidism can produce cognitive, autonomic, and motor symptoms, and thyroid-stimulating hormone (TSH) is the standard screen.

    In regions where Lyme disease is common, or with a compatible exposure history, Lyme serology is worth including, with the understanding that the tests have limits and a result needs interpretation rather than a glance. Celiac disease can produce peripheral neuropathy, ataxia, and cognitive symptoms, sometimes as the presenting features. Tissue transglutaminase immunoglobulin A (IgA) with total IgA is the screening combination.

    Other demyelinating conditions, including neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG) antibody disease, have their own antibody tests, as does autoimmune autonomic neuropathy, and a neurologist will know when the picture calls for them.

    Medication effects deserve a full review. Not only benzodiazepines but also fluoroquinolones, metronidazole, chemotherapy agents, statins in some patients, and other medications can produce neurological symptom pictures. The full medication list belongs in every workup of this kind.

    Functional neurological disorder (FND) has specific rule-in criteria and should not be a diagnosis of exclusion after a normal workup. The clinician should test for FND signs specifically (Hoover’s sign, tremor entrainment, tubular visual fields) and apply the label only when they are present, not when everything else is negative.

    Where the Diagnostic Error Usually Happens

    The typical failure mode in this clinical scenario is a neurologist who completes an MS workup, finds it negative, and concludes “no neurological disease.” The symptoms are then attributed to anxiety, functional etiology, or somatization, and the patient is referred back to psychiatry or discharged from neurology follow-up.

    This is an error for several reasons.

    MS-negative does not mean neurological-disease-negative. The MS differential is narrow; many non-MS neurological conditions produce similar symptom pictures and require different tests to identify.

    BIND is a neurological condition, not a psychiatric one, even though it lacks the structural imaging findings of classical neurology. It is also a condition of physical dependence, which is not addiction: the nervous system adapted to a prescribed medication and is now destabilized by its reduction or absence, and nothing about that requires a psychiatric or addiction explanation. A neurologist who does not consider pharmacologically-driven neurological dysfunction as part of the differential is working with an incomplete framework.

    Defaulting to FND without rule-in criteria produces the same misdiagnosis pattern seen elsewhere on this site, where BIND is relabeled as an unrelated condition, and the same collision plays out when BIND is mistaken for fibromyalgia. FND exists as a positive diagnosis; it is not “everything else has been ruled out.”

    What the Patient Can Ask For

    For a patient headed into an MS workup in the context of a benzodiazepine history, several requests shift the evaluation toward a more useful outcome.

    Ask that the benzodiazepine history and taper timeline be explicitly documented in the neurology note. A workup pursued in the context of acknowledged benzodiazepine exposure produces more useful subsequent discussion than a workup that implicitly treats the patient as free of relevant medication history.

    Request that BIND be considered as one possibility alongside MS. Providing background on the BIND framework in advance can orient a neurologist unfamiliar with it.

    Ask that the workup include B12, methylmalonic acid, homocysteine, vitamin D, TSH, celiac serology, and Lyme serology (where exposure is plausible) alongside the MRI and CSF. These are low-cost additions that broaden the differential meaningfully.

    If the MS workup is negative, request that the neurologist document specifically which diagnoses are being considered next rather than defaulting to “non-neurological” or “functional.” A differential explicitly including BIND, mimic conditions, and specific alternative neurological diagnoses is more useful for future clinical care than a negative conclusion.

    Ask for follow-up rather than discharge if BIND is being considered. BIND patients benefit from neurology follow-up even when the structural workup is negative; autonomic and sensory symptoms may require specific management, and the label of a recognized syndrome in the chart aids subsequent care.

    What a Good Neurology Note Looks Like

    For a BIND patient whose MS workup returned negative, a well-constructed neurology note reads something like this: structural MS workup is negative; the clinical picture is compatible with benzodiazepine-induced neurological dysfunction; alternative mimics (B12 deficiency, thyroid dysfunction, Lyme disease, celiac disease) have been evaluated and are not contributory; ongoing management will focus on the benzodiazepine taper and recovery with follow-up at regular intervals.

    Compared to a note that says “no evidence of neurological disease; recommend psychiatric follow-up,” the useful version accomplishes several things: it acknowledges the syndrome by name, documents the negative workup in context, aligns future clinicians with the relevant framework, and preserves the clinical relationship for ongoing care.

    The point of an MS workup in a BIND patient is to exclude MS. The workup accomplishes that efficiently when pursued appropriately. What matters equally is that the broader differential is considered from the start, so that a negative MS workup narrows the question rather than ending it.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • How Should a Doctor Answer When a BIND Patient Asks If They Will Ever Fully Recover?

    How Should a Doctor Answer When a BIND Patient Asks If They Will Ever Fully Recover?

    Will you ever fully recover?

    Will you ever fully recover from benzodiazepine-induced neurological dysfunction, or BIND? It is the hardest question you can put to your doctor, and the one most often answered badly. You may be the patient asking it, or the family member who has been asking it silently for months.

    There are two ways for a doctor to get it wrong. False reassurance, the promise that you will be fine by some date, sets you up to feel like a failure when the date passes. False certainty, the flat statement that this is permanent, pushes a person toward despair over an outcome most people never meet.

    The honest answer lives between those two failures. Most people improve, the course is uneven, the timeline runs months to years, no one can predict your case, and nothing reliably hurries it along. So, what does that answer sound like across a desk?

    Which recovery are you asking about?

    Before you ask, it helps to know what you mean by “full.” For some people it means the complete absence of symptoms and a return to the person they were before. For others it means being able to work, sleep, and get through a day without symptoms running it, even if a few linger.

    They are two different questions. In clinical experience, functional recovery is what most people eventually describe, often with a residual symptom, while complete symptom resolution is the higher bar and comes later, if it comes. A good doctor will ask which one you mean, and if yours does not, tell them.

    Most people improve, and the Ashton Manual says so.

    The first honest statement is that most people get better. The Ashton Manual, in its chapter on withdrawal symptoms, says that with slow tapering the majority of long-term users lose their symptoms within a few months, while a minority are left with protracted symptoms lasting months or years. Its supplement adds that by far the greatest majority do recover, given time.

    The same chapter matters even more for the minority. All the evidence, in Professor Ashton’s words, shows that a steady decline in symptoms almost invariably continues after withdrawal, though it can take a long time. Even protracted symptoms, the supplement says, tend to decrease gradually, sometimes over years.

    The course runs in windows and waves.

    The second honest statement is that recovery is uneven. The Ashton Manual describes symptoms that wax and wane from day to day and week to week, with “windows” of feeling well that appear after some weeks and gradually grow more frequent and longer. Patients call the bad stretches waves.

    Unfortunately, no one warns you that the pattern feels like failure from the inside. A wave after a good window is not evidence that you are going backward, and the Ashton Manual notes that a severe stress can temporarily bring back symptoms even late in the course.

    A homely comparison may help, though it is not a perfect one. A garden after a hard winter comes back unevenly, some beds green in March and some bare until late spring. Digging up the bare patch to check on it does more harm than the frost did, so leave the roots alone and keep watering.

    Timelines are measured in months to years.

    The third honest statement is about the clock. A conversation that implies resolution within weeks sets you up for a fall, and the 2020 United States Food and Drug Administration (FDA) update to the benzodiazepine label acknowledges withdrawal symptoms lasting many months, with reports lasting from weeks to years. Months to years is discouraging to hear, and it is also the truth.

    The fourth follows from it. Yet, no one can reliably predict how long your case will take, because the range is wide and the individual course only becomes clear in hindsight. The Ashton Manual says it is impossible to give an exact time for the duration of withdrawal symptoms, and while that is less than you want, it is more than a number that will turn out to be wrong.

    Nothing reliably speeds recovery.

    The fifth honest statement is the one people least want. In clinical experience, no medication, supplement, or protocol reliably shortens the course of BIND, and the evidence here is thin enough that the gap should be said plainly rather than filled in with hope. Some patients find a particular approach soothing, but that is an individual finding, not an accelerant for the next person.

    Supplements, diets, and complementary approaches are individual decisions to make with your own physician, with no blanket endorsement or prohibition. Healing, of body or mind, is a slow process, as the Ashton Manual’s chapter on how to withdraw puts it.

    Which answers should worry you?

    Four answers should make you cautious. The first, “you’ll be fine in six months,” predicts a date that most people will not meet. Of course, a prediction of six months is easy to give and impossible to keep, which may be why it is so popular.

    A common pattern shows the cost. A patient told that six months will do it reaches month seven still unwell, stops reporting honestly, and reads forums at three in the morning instead of talking to the doctor who set the date.

    The second, “there’s nothing wrong with you, your scans are normal,” confuses a normal picture with a healthy nervous system. The Ashton Manual reports nerve conduction studies that found nothing abnormal in patients whose symptoms were real, and it finds no evidence of permanent structural damage. Neither fact means your symptoms are imagined.

    The third, “you’ll never fully recover,” predicts an outcome that the steady decline in symptoms argues against for most people, with a certainty no one has earned. The fourth, “have you considered that this might be anxiety or depression,” turns a nervous system injury into a diagnosis of the person. Anxiety and low mood are real in BIND and deserve attention, but a psychiatric label must not replace the diagnosis you actually have.

    What supports recovery?

    What helps is mostly ordinary. Time is the main ingredient, and after it come regular sleep, paced activity rather than a forced return to full function, and a taper that is never rushed or stopped abruptly, since the FDA label warns that stopping suddenly or cutting too fast can cause withdrawal reactions including seizures. Decisions about pace belong to you and your prescriber together.

    In fact, avoiding re-exposure matters as much as anything already named. The Ashton Manual, in its chapter on how to withdraw, advises against making up for the missing benzodiazepine with alcohol or non-prescription drugs, and it warns against the sleeping tablets zolpidem (Ambien), zopiclone, and zaleplon because they have the same actions as benzodiazepines, the action its first chapter describes at the receptor for gamma-aminobutyric acid, or GABA. Its supplement adds that quinolone antibiotics, the family that includes ciprofloxacin, displace benzodiazepines from their binding sites and should not be taken by people on, or recently on, benzodiazepines.

    The last support is being believed, starting with the right category, and in Dr. Leeds’ experience it is not a soft one. Physical dependence is not addiction. You took a medication as prescribed, your nervous system adapted to it, and what you are living through now is that adaptation coming undone, a medical condition that is treated as one.

    Patients whose doctors understand this seem to do better over the long course. While that is an observation from practice rather than a study, it is a consistent one.

    What if a symptom is new or frightening?

    An honest prognosis comes with one caution. BIND can reach nearly every system of the body, from tinnitus and muscle spasms to nerve pain, so it is tempting to file everything under withdrawal. A symptom that is new after a long stable period and keeps worsening, or one that is strictly one-sided, deserves a workup rather than a shrug.

    Weakness or numbness on one side, trouble speaking, a first seizure, chest pain, fainting, or a high fever with a stiff neck should be checked before anyone calls them withdrawal. If you have a seizure, chest pain, sudden loss of vision or hearing, or thoughts of harming yourself, call 911 or go to the nearest emergency department, and you can call or text the 988 Suicide and Crisis Lifeline. Despair is common in a long course, and it is a reason to be seen, not a reason to be quiet.

    What does a good answer from your doctor sound like?

    Now you know what to listen for. A good answer admits that the question is hard, then names the range honestly: most people improve, the timeline is long, and no one can predict a single case. It asks which recovery you mean, warns you about the windows and waves so the first bad week does not feel like a verdict, says what cannot be promised, and offers to stay involved whatever the course turns out to be.

    If the answer you get is missing most of those pieces, you are allowed to ask someone else. “I do not know, but here is the range” is a steadying thing to hear, because it means the person across the desk is looking at you rather than at the calendar. Fortunately, the range itself is on your side. Time is the part no one can hurry, and it is also the part that has been doing most of the healing all along.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • When Benzodiazepine-Induced Neurological Dysfunction (BIND) Is Misdiagnosed as Functional Neurological Disorder, How Do You Get the Chart Corrected?

    When Benzodiazepine-Induced Neurological Dysfunction (BIND) Is Misdiagnosed as Functional Neurological Disorder, How Do You Get the Chart Corrected?

    Why does a functional label follow you from one doctor to the next?

    Because a chart never forgets and rarely reconsiders. When benzodiazepine-induced neurological dysfunction, or BIND, is written up as functional neurological disorder, or FND, the label does not stay in one neurologist’s note. It travels, and every clinician who opens the record afterward reads it before they read you.

    It shapes how a new tremor gets interpreted, which specialists will accept a referral, and whether an insurer will pay. Yet, the label was usually applied in good faith, by a doctor working inside a framework that has no line for BIND.

    So, why does the mix-up happen, and what changes the record once it has? The second answer is paper.

    What is BIND, and why does it look like nothing on a scan?

    BIND is the name for the neurological, cognitive, and autonomic symptoms that can persist after long-term benzodiazepine use, including in people who tapered slowly and did everything right. The symptoms begin during use, during dose reductions, or after the last dose, and that timing is the heart of the diagnosis.

    Professor C. Heather Ashton described the picture years ago without the acronym. Chapter III of the Ashton Manual, in its Table 3 of protracted withdrawal symptoms, lists tinnitus, tingling, numbness, burning limb pain, muscle pain, cramps, tremor, jerks, and shaking attacks, and says they gradually recede but may last at least a year and occasionally several. The 2020 United States Food and Drug Administration (FDA) label update says as much: physical dependence can occur when a benzodiazepine is taken steadily for several days to weeks, even as prescribed, and a protracted withdrawal syndrome can last from weeks to as long as twelve months.

    Why is the scan normal? The first chapter of the Ashton Manual describes the receptors benzodiazepines act on becoming less responsive during long use. One theory is that they recover slowly afterward, a change in how the nervous system is tuned rather than in its structure, and no routine test measures tuning.

    Functional neurological disorder is supposed to be a rule-in diagnosis.

    FND is a real diagnosis, and a neurologist is supposed to make it on positive findings rather than on the absence of them. The rule-in signs are specific: Hoover’s sign for functional weakness, tremor that falls into step with a rhythm the examiner sets, and movements that stop when your attention is pulled elsewhere.

    In practice it is not always arrived at that carefully. A normal magnetic resonance imaging (MRI) scan, a normal electroencephalogram (EEG), and no fit to a standard syndrome, and the note says functional because nothing else was on the menu. That default is where the BIND patient gets caught, and the Maudsley Deprescribing Guidelines make the point that withdrawal effects are often mistaken for a return of the original condition or for a new physical or mental health condition.

    Three things about BIND make the mix-up easy.

    First, the tests are normal. There is no MRI finding for BIND and the EEG shows no seizure activity. Professor Ashton recorded three patients whose numbness, spasms, and double vision were diagnosed as multiple sclerosis, a label that disappeared with the symptoms once they were off the drug. The same pattern appears in other specialties when jaw tension and neck dystonia in withdrawal are read as temporomandibular disorder.

    Second, some BIND signs look functional on the surface. Tremor that waxes and wanes, symptoms that shift with attention, and bad days followed by ordinary ones are all real in BIND, and all sit on the list neurologists are taught to read as functional.

    Third, the medication history is thin in the chart. If your years on a benzodiazepine and the taper that followed are not at the top of the history, the neurologist may never connect the picture to the drug. And, when the taper is recorded, it usually reads “completed uneventfully six months ago,” which few neurologists are trained to weigh as a live variable.

    Start with a written medication timeline.

    The most useful document you can bring is one page. It lists the benzodiazepine by name, the dose, how long you took it, how the taper went and when it ended, and beside that, when each symptom began and how it has behaved since. Ask that the page be scanned into the chart as a document, not summarized by whoever is typing.

    Write it in the vocabulary of prescribed dependence. If the chart files your Klonopin (clonazepam) under past habits rather than under prescribed medications, every later reader starts from the wrong premise. Physical dependence is not addiction. A person who took a medication as prescribed and now has symptoms after stopping it has a medical condition caused by the medication, and a timeline that says so plainly does more work than any argument in a visit.

    While you are writing it, resist any urge to prove a point by changing your taper. The 2020 label update is explicit that stopping a benzodiazepine abruptly, or reducing it too quickly, can bring on withdrawal reactions, including seizures, that can be life-threatening.

    Ask that BIND be named, with its expansion.

    Clinicians write what they are given. A short line you hand over, “presentation consistent with benzodiazepine-induced neurological dysfunction (BIND) following prescribed use and a completed taper,” gives the record a searchable term the next clinician can act on, and preserves the fact that the injury was iatrogenic, meaning caused by treatment.

    Bring supporting material, kept short. The 2020 FDA label update is the strongest single page, because its boxed warning, which your neurologist can look up, says continued use can lead to clinically significant physical dependence. The Maudsley Deprescribing Guidelines are a reference text neurologists recognize, and the Benzodiazepine Information Coalition, or BIC, on whose medical advisory board Dr. Leeds serves, publishes clinical resources written for this conversation.

    If FND is already in the chart, ask for a written amendment.

    The Health Insurance Portability and Accountability Act, or HIPAA, gives you the right to ask that a record you believe is inaccurate be amended. The request goes in writing to the practice or hospital that created the note, and a refusal must come back to you in writing, ordinarily within sixty days. Keep it factual: the diagnosis does not reflect the medication history and the symptom chronology, and you are asking that BIND be added, alongside FND or as a correction.

    They may say no. Unfortunately, a denial by itself does not make your request travel with the record. What does is a statement of disagreement, a short written note you file after the denial. Once it is on file, the provider must include your request, the denial, and your statement whenever that part of the record is disclosed, and without it they are included only if you ask for that separately.

    So, if the answer is no, file the statement. It is the step most patients skip, and the one that does the work. If the answer is yes, ask which records were amended and whether the correction reached the other clinicians who received the original.

    Ask that the negative findings be written down.

    There is a difference between a note that says “functional etiology suspected” and one that says “Hoover’s sign negative, tremor did not entrain, FND rule-in signs tested and not present.” The first is an impression. The second is a set of findings, and findings are what the next neurologist reads.

    So, when an examiner tests for those signs and does not find them, ask that the absence be recorded affirmatively, and ask in the room. That small request quietly removes the floor from under a functional label.

    The record is changed with paper, not with persuasion.

    Do not argue the diagnosis in the visit. The mechanism that produced it is institutional, fifteen-minute appointments and diagnostic defaults, and none of that is reversed by one patient disagreeing well.

    Do not avoid mental health care out of fear that it confirms the functional label. BIND regularly brings anxiety, low mood, and trauma responses that deserve care in their own right, and treating them does not retroactively validate an FND diagnosis. Choose it with open eyes, since standard psychiatric treatment can make BIND worse, and if thoughts of harming yourself appear, call or text 988 or go to the nearest emergency department.

    And do not let “it is probably BIND” become a label of its own. New weakness or numbness on one side of the body, a first seizure, a sudden loss of vision or hearing, a severe sudden headache, chest pain, or trouble speaking need emergency care the same day, whatever the chart says. BIND explains a great deal, and it does not explain everything.

    The clinicians who wrote the label are usually not the problem.

    Most neurologists who apply an FND label do it in good faith, within a diagnostic framework that has not yet made room for BIND, and the path forward is clinician education more than confrontation. Over time the label often softens and drops out of later notes as the paper keeps arriving.

    Fortunately, this is a syndrome with a direction. The Ashton Manual says that a steady decline in symptoms almost invariably continues after withdrawal, though it can take a long time, and a record corrected one page at a time tends to lag behind the nervous system it describes. You will probably be better before the chart catches up, and the pages you filed will still be there for whoever reads it next.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Can Low-Dose Naltrexone Help With the Symptoms of BIND?

    Can Low-Dose Naltrexone Help With the Symptoms of BIND?

    Why do patients with BIND keep asking about low-dose naltrexone?

    Can low-dose naltrexone help with the symptoms that linger after a benzodiazepine is gone? The honest answer is that nobody knows. Benzodiazepine-induced neurological dysfunction, or BIND, is the name the patient and clinical community uses for the symptoms that can persist for months or years after a benzodiazepine has been tapered and stopped, even when the taper was done carefully.

    Burning or tingling skin, a mind that will not hold a thought, sound that hurts, a heart that races at nothing, broken sleep, and a morning dread that lifts by afternoon are the ones patients describe most often. After a year of that, a person will read about anything, and low-dose naltrexone comes up on nearly every patient forum.

    It comes up because it has a story attached: that BIND might be sustained by lingering immune activity in the brain, and that this medication, at a very low dose, might quiet it. So, is the story true? The answer is less satisfying than the story.

    What is low-dose naltrexone, in plain words?

    Naltrexone is an older prescription medication that, at full strength, blocks a receptor system that has nothing to do with the GABA receptors where benzodiazepines act. GABA stands for gamma-aminobutyric acid, the brain’s main calming signal, and the whole benzodiazepine problem lives there. Naltrexone does not touch it.

    Low-dose naltrexone, or LDN, means the same medication given at a small fraction of its full strength. At that fraction, the thinking goes, it does something different, and that difference is why anyone is interested.

    The United States Food and Drug Administration (FDA) label for naltrexone describes the full-strength tablet and its approved uses, and it says nothing about the very low doses used as LDN. Every low-dose use is off-label, which is legal and common, and it means the label cannot tell you much about what to expect.

    The name puts some people off, and it should not.

    At full strength, naltrexone has a long history in addiction medicine, for unrelated conditions, and some patients hear the name and hear an accusation. While that reaction is understandable, the premise behind it is wrong.

    Physical dependence is not addiction. Dependence is what a nervous system does when a medication has been present long enough for the brain to adapt around it, and it happens to people who never once misused a pill. A low dose of this medication for a different purpose says nothing about you either.

    What is the theory that connects it to BIND?

    Chapter III of the Ashton Manual, on withdrawal symptoms, sets out in its Table 4 the possible causes of protracted symptoms. Nervous system hyperexcitability from persisting changes in GABA and benzodiazepine receptors is listed there without a question mark, while structural or functional damage to brain tissue and changes in the gut and immune systems carry one, which the table defines as a mechanism with no scientific evidence yet.

    Yet, the same chapter notes that benzodiazepine use or withdrawal may affect immune responses. One theory in the patient and clinical community runs with that thread: perhaps the brain’s own immune cells, activated during long exposure and withdrawal, stay activated and keep the nervous system on edge after the receptors should have recovered.

    A rough analogy, and an imperfect one, is a house where the fire is out but the smoke alarm will not stop. The fire was the benzodiazepine, the alarm is the immune activity, and LDN is proposed as a way to reset the alarm. While this is not a perfect analogy, it tells you what to expect at best: a quieter alarm, never a rebuilt house, and no shorter wait for the rebuilding.

    Is there any evidence that it works for BIND?

    No. There are no studies of low-dose naltrexone in BIND that anyone can point to, and none in protracted benzodiazepine withdrawal. The immune theory is a hypothesis, and a hypothesis with a good story is still a hypothesis.

    Medicine is full of plausible mechanisms that never became treatments. Unfortunately, the science behind LDN in BIND has not been done, and what exists instead is clinical experience, which varies.

    What do patients who have tried it report?

    A common pattern goes like this. A patient a year or two off a benzodiazepine, still living with burning skin and a mind that will not settle, tries LDN under a physician’s care and reports, a few weeks in, that the pain sits a little further away and the mornings are less dreadful. Nothing dramatic, but a change worth keeping.

    Just as common is the other pattern. The same kind of patient starts LDN and, within days, reports vivid dreams, worse sleep, a wired restlessness, or a wave of anxiety and nausea. A sensitized nervous system reacts to almost every new input, and some of those patients decide, sensibly, that it is not for them.

    A bad first week does not mean a person did anything wrong. And, a good month does not prove the medication did it, because BIND improves on its own over time, unevenly, so both patients above may be right about what they felt and wrong about why.

    What does the medication’s own label say you should know?

    The naltrexone label describes the full-strength tablet, and its cautions are written for that strength, yet some matter at any dose. It advises carrying identification saying you take naltrexone and telling every physician who treats you, because certain prescription pain medicines used after surgery or injury may not work while it is in your system. Say so to your surgeon and your dentist before a procedure, not after.

    Beyond that, the label warns of liver injury and advises seeking medical attention for symptoms of hepatitis, so your doctor should know your liver history before prescribing any strength. Among the most common side effects it lists at full strength are nausea, headache, dizziness, nervousness, fatigue, insomnia, and anxiety, a list that reads like BIND itself, which is why a person with BIND cannot always tell a side effect from a wave.

    If a new symptom is chest pain, a seizure, a sudden loss of vision or hearing, or thoughts of harming yourself, that is emergency care today, whatever else you are trying, and the 988 Suicide and Crisis Lifeline is there for the last of those.

    It has to be compounded, and it has to be reviewed.

    Low-dose naltrexone is not a product you can pick up at a chain pharmacy. The doses used are a small fraction of the manufactured tablet, so a compounding pharmacy has to make it, from a prescription written by a physician who has decided, with you, that a trial is reasonable. In practice, that means it is not a self-help project, and it means being wary of anyone selling it outside that arrangement.

    The decision is individualized, weighing the symptoms, how reactive the nervous system has been to other inputs, what else is being taken, and what has already been tried, and some patients will not be candidates at all. Every reasonable trial has review points. The cautious position is that a trial should have a date on which patient and physician decide together whether it is helping, and that it should be as easy to stop as it was to start.

    An open-ended trial with no decision rule is how a person ends up on a medication for two years without knowing whether it did anything.

    It never replaces a slow taper, and it does not buy back time.

    If you are still taking a benzodiazepine, low-dose naltrexone is not a shortcut. It does not treat withdrawal, and it is never a reason to speed up a taper or to stop abruptly. The Maudsley Deprescribing Guidelines describe protracted withdrawal syndromes lasting months or years after benzodiazepines and recommend a slow, hyperbolic taper adjusted to what the person can tolerate, and no adjunct changes that.

    The 2020 FDA benzodiazepine label update acknowledged a protracted withdrawal syndrome whose symptoms may last weeks to as long as 12 months. Professor Ashton wrote, in the same chapter of the Manual, that a steady decline in symptoms almost invariably continues after withdrawal, though it can take a long time, even several years in some cases. Time is the one treatment for BIND that everyone agrees on, and no adjunct has been shown to shorten it.

    So, the most that can be hoped from LDN is that some symptoms sit a little further away while the slow work goes on underneath. For a person in pain that is worth something, and it is a long way from a cure.

    So, where does that leave you?

    Is a cautious, reviewed trial of a low-dose medication worth trying for symptoms that have already lasted a long time? Some patients and their physicians will decide yes, some will decide no, and neither is the wrong decision on the evidence we have.

    Your doctor wants to hear the question, and a doctor who has seen BIND will not be surprised by it. Bring the label’s cautions, your own history of reactions to new medications, and a willingness to stop if it is not helping. Fortunately, the recovery that matters is already under way, with or without any of this.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Does Long-Term Klonopin Cause Emotional Blunting? What Patients Describe but Doctors Miss

    Does Long-Term Klonopin Cause Emotional Blunting? What Patients Describe but Doctors Miss

    Does long-term Klonopin cause emotional blunting?

    For many people, yes. Clonazepam, sold as Klonopin, is a long-acting benzodiazepine, and years of daily use commonly narrow the range of what a person can feel. The Ashton Manual, in Chapter I under the heading “Depression, emotional blunting”, calls this “emotional anaesthesia”, the inability to feel pleasure or pain, and describes it as a common complaint of long-term benzodiazepine users.

    You will rarely find it in your chart. Patients notice it years into treatment, if they notice it at all, and most file it under getting older or being stably medicated.

    So, two questions follow. Why does a change this large go unrecorded for years, and what happens to it when the drug is slowly withdrawn?

    You still feel, just less of everything.

    Patients reach for the same picture: a volume knob turned down on the whole board at once rather than on a single channel. Grief is quieter, and so are joy, irritation, and desire. A child’s graduation or a parent’s funeral registers as the event it is, and the feeling arrives at half strength.

    What sets this apart from depression is that you know what is missing. A person in a deep depression often cannot picture ever having felt otherwise, while a blunted patient remembers full emotional range clearly and can describe the gap.

    Daily life usually continues. Yet, patients describe watching their own lives with less investment, or, in a phrase many of them use, sleepwalking through them. Another phrase that comes up again and again is “I can’t cry”, from someone standing dry-eyed in situations that should bring tears and aware of it.

    Why does nobody mention it at the visit?

    Because you do not lead with it. You come in with anxiety, sleep, or a physical symptom, and “I feel less than I used to” is not a complaint most people think to make. It tends to be volunteered only when someone asks directly, or when a taper makes the contrast available.

    The prescriber’s side has its own blind spot. A patient who is less reactive, less tearful, and less easily rattled can look, from across the desk, like one whose anxiety is finally well controlled. In medicine, we are good at asking about sadness and poor at asking about range, so the loss goes unrecorded and the prescription is renewed.

    Unfortunately, the people around you often notice first. The Ashton Manual observes that former long-term users often bitterly regret their lack of emotional response to their children and partners during the years on the drug, and the toll on families deserves its own telling.

    Is it depression, or is it the drug?

    Often it is read as depression, and the reading is understandable. Less pleasure, less engagement, and no tears are three things a mood questionnaire asks about. A patient who endorses them is usually offered an antidepressant, most often a selective serotonin reuptake inhibitor, or SSRI, and the benzodiazepine that may be causing the flatness goes unexamined.

    In Dr. Leeds’ experience, that second medicine rarely restores what the first one took, and many patients report feeling flatter still with both on board. When the antidepressant produces no lift, that is sometimes read as a partial response calling for a higher dose or a third drug, which is the shape of a prescribing cascade: a drug’s effect treated as a new disease.

    Yet, the two can coexist, and the Manual is careful on the point. It notes that long-term users are often depressed, that the depression may first appear during prolonged use, and that benzodiazepines can both cause and aggravate it. Klonopin’s own label lists depression among the adverse reactions in its panic disorder trials and warns that antiepileptic drugs, clonazepam included, can increase the risk of suicidal thoughts or behavior.

    So, flatness on long-term clonazepam deserves a look at the clonazepam before a diagnosis is added, without assuming the drug explains everything. If you are having thoughts of harming yourself, that comes before any taper question. Call or text 988, the Suicide and Crisis Lifeline in the United States, or go to the nearest emergency department, and let the sorting-out come afterward.

    Why would a calming drug flatten feeling?

    Nobody knows in detail, and it is better to say so. The Ashton Manual, in the same passage, says the blunting is “probably related to the inhibitory effect of benzodiazepines on activity in emotional centres in the brain”, and one way to read that is that the inhibition which quiets anxiety cannot leave feeling alone. Going back to the volume knob, there is no separate channel for dread.

    While this is not a perfect analogy, it fits what patients report: short courses rarely do this, and years at ordinary prescribed doses commonly do. Ask whether the dial has moved, then, because you are the only person who can hear the difference.

    Does a slow taper bring feeling back?

    Usually, and slowly. The Ashton Manual does not track this symptom on its own, but Chapter III says that in most people withdrawal symptoms disappear within a few months and that a steady decline almost invariably continues after withdrawal. Blunting, in Dr. Leeds’ experience, follows that pattern: most people regain range, some regain it completely, and some carry a degree of flatness for a long time afterward.

    The timeline is months rather than weeks, and feeling often returns in patches before it settles. A person who has not cried in a decade may find tears arriving over a song midway through a taper, and grief that was muted years ago can surface with its original weight. Most patients call this welcome even when it is uncomfortable, because it means the range is returning.

    Not everyone gets all of it back. A minority describe blunting that persists into protracted withdrawal, in some cases for years, though even then it tends to improve slowly rather than not at all. Whether that reflects a lasting change from prolonged exposure, a separate condition the drug had masked, or one face of benzodiazepine-induced neurological dysfunction, or BIND, is an open question.

    Why does it have to be a taper rather than a stop?

    Years of daily clonazepam produce physical dependence, meaning the nervous system has adjusted itself around the drug and now needs it to hold steady. Physical dependence is not addiction. It was created by a prescription taken as directed, not by urges or misuse, which is why the way out is medical and gradual rather than a matter of willpower.

    Klonopin’s label, which carries the Food and Drug Administration’s 2020 boxed warning for all benzodiazepines, states that abrupt discontinuation or rapid dosage reduction after continued use may precipitate acute withdrawal reactions, which can be life-threatening, and that a gradual taper reduces that risk. It also acknowledges a protracted withdrawal syndrome lasting weeks to more than a year.

    So, do not stop clonazepam on your own or skip doses to test whether feeling returns. A seizure is one possible answer, and a seizure after a missed or reduced dose is an emergency: call 911.

    How slow is slow enough is worked out between you and your prescriber. The Ashton Manual’s schedules and the Maudsley Deprescribing Guidelines both describe small reductions held long enough for the nervous system to catch up, with the Maudsley approach making each step smaller as the dose gets lower. The pace is set by how you tolerate each step, never by a calendar.

    What should you ask for at your next visit?

    Start with one question the standard mood screen does not ask: “Do I feel emotions with the same intensity as before I started this medication?” Put it to yourself first, then to your prescriber in those words, because it opens a conversation that “How is your anxiety?” never will.

    Then look at the timing together. Blunting that began in the first year on the drug and has held steady since points toward the medication. Flatness that arrived recently in someone stable on clonazepam for a decade deserves a wider look: a new medicine, a recent loss, a medical problem such as thyroid disease, or a depression of its own.

    Some signs mean this needs checking now rather than watching: sudden onset, hopelessness, thoughts of death, new confusion, or marked changes in weight or sleep. Those are not taper questions, and they should not wait for the next visit.

    Fortunately, the trade-off itself is plain. If clonazepam is still doing real work for a hard anxiety condition and the flatness is mild, continuing may be a reasonable choice, and it is yours to make. If the flatness troubles you most and the reason the drug was started has passed, a slow taper is the conversation worth having, decided with your prescriber and never started alone.

    Keep a record while you decide, and during any taper. A few lines a week on what you felt and how strongly gives the next visit something better than recall, and it lets you see the dial move in a direction too slow to notice day to day.

    Naming the quiet out loud, to yourself and then to your doctor, is usually the first thing that changes. And, for most people, the range does come back, at a pace set by the nervous system rather than by anyone’s wishes. Somewhere in the months of a careful taper, something ordinary will land with its full weight, and you will know it when it does.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • What to Look for in a Doctor Who Understands Protracted Withdrawal

    What to Look for in a Doctor Who Understands Protracted Withdrawal

    Why is it so hard to find a doctor who understands protracted withdrawal?

    Because most doctors were taught that benzodiazepine withdrawal is over in a few weeks. A patient whose symptoms last longer does not fit the model, so the patient is told the problem is anxiety. In fact, the 2020 United States Food and Drug Administration (FDA) benzodiazepine label update says withdrawal symptoms can last months, but a label change does not reach every examination room.

    The clinician who understands protracted withdrawal is usually one who read into it on their own time, often because a patient made them. That is a small population, with no directory. So, the useful question is how to recognize one of them before the first visit, or within it.

    They use the vocabulary, and they mean it.

    A doctor who works with this population speaks a particular language. Protracted withdrawal, the term for symptoms that outlast the acute phase, and benzodiazepine-induced neurological dysfunction, or BIND, the newer name for symptoms that persist after the drug is gone, are working terms in such a practice. So are tolerance withdrawal, meaning symptoms that appear while the dose is unchanged, and kindling, the tendency of each abrupt stop or fast cut to make the next one worse.

    Yet, vocabulary alone proves little, since anyone can learn the words. A clinician who asks what your taper schedule looks like and what happened after the last cut is working from the framework, while one who asks whether you are off the benzo yet is not.

    They know the source documents.

    Three documents anchor this work, and you can ask about them by name. The Ashton Manual, written by Professor C. Heather Ashton, sets out the slow taper in Chapter II and describes the protracted symptoms in Chapter III. The Maudsley Deprescribing Guidelines give the modern method of proportional reductions, and the 2020 FDA label update put physical dependence and withdrawal into the boxed warning on every benzodiazepine. A clinician who can name any of these unprompted is working from them, and one who has heard of none may be teachable, but you will be doing the teaching.

    They expect windows and waves.

    Withdrawal does not run in a straight line, and the protracted form least of all. Chapter III of the Ashton Manual says of withdrawal generally that symptoms characteristically wax and wane, varying in severity and type from day to day, week to week, and even during the course of a day. Patients call the good stretches windows and the bad ones waves.

    A doctor who does not know the syndrome reads a wave as deterioration or as proof that the problem was always psychological, while one who knows it names the pattern, checks that nothing new is going on, and does not tear up the plan over one bad week. That checking matters: a new chest pain, a seizure, a sudden loss of vision or hearing, or any thought of harming yourself is examined as what it might be, and the emergency room is the right place for those, taper or no taper. If you are thinking of harming yourself, call or text 988 now.

    They let you set the pace.

    The Ashton Manual is unusually blunt here. Chapter II tells you to stay in control of your own schedule, and not to let your doctor impose a deadline.

    Dr. Leeds’ own view is that a taper should be patient directed, with the doctor advising a slower pace when reductions are too fast and agreeing to a faster one when the patient tolerates them. A clinician who says at the first visit that you need to be off this in six months is working from a calendar that your nervous system has not seen.

    Three questions tell you whether the method is real.

    Many clinicians now say hyperbolic tapering, which means reductions calculated as a percentage of the current dose, so the steps get smaller as the dose falls. Some use the phrase and the method, some use only the phrase, and three questions, asked on a phone call, separate them.

    First, ask how the size of each reduction is calculated as the dose gets lower. The answer you want is a percentage of the current dose, with steps that shrink toward the end, which is roughly how the Ashton Manual’s own schedules are built, with the steps shrinking as the dose falls, and is explained in What Is the Ideal Cut Percentage?. A fixed amount at fixed intervals is a linear taper, whatever it is called.

    Second, ask whether the practice uses liquid or compounded formulations for the low end. The Ashton Manual notes that liquid preparations allow slow reduction by decreasing the volume of each dose with a graduated syringe. A clinician who has never prescribed one has fewer options when the tablet steps at the low end become too large for you, and finding a compounding pharmacy is easier with a prescriber who has done it before.

    Third, ask what happens if you have a bad reaction to a reduction. The answer you want includes holding the dose until you are steady. While the Ashton Manual advises standing still for a few weeks rather than going backwards, some clinicians will return you to the last dose you tolerated, and either answer shows a plan for a bad week. A plan to keep reducing on schedule regardless is the disqualifying answer.

    What they do not do tells you as much.

    A clinician who understands protracted withdrawal does not meet every new symptom with a new prescription. New symptoms here are candidates for tolerance withdrawal or evolving BIND first, and a doctor whose reflex for a bad stretch is to add a selective serotonin reuptake inhibitor (SSRI), an antipsychotic, or a sleeping pill has not understood what the bad stretch is. Individual judgment still happens in the room, of course.

    They do not blame your personality, though “anxious patient” sits in the charts of many people whose symptoms are physical and time-locked to their doses. They do not hand you a written schedule with no way to adjust it, and they do not push you through a flare because the schedule says so. And, they do not require a new psychiatric label to keep seeing you: benzodiazepine withdrawal has a diagnostic code, but BIND and protracted withdrawal have none, so some clinicians relabel the syndrome as an anxiety disorder because the chart needs something in the box.

    Where do these doctors come from?

    From everywhere, and from nowhere in particular. Family medicine, internal medicine, psychiatry with a deprescribing interest, and addiction medicine each contain a few clinicians who do this work well and many who do not, so specialty predicts little and practice emphasis predicts a lot.

    A patient who took a benzodiazepine as prescribed and whose nervous system adapted to it has a physical dependence, and physical dependence is not addiction. That patient has a medical condition caused by the prescription, treated with a gradual taper rather than an addiction program, and the best addiction medicine clinicians know this while the worst run detox clinics that do not. Patient communities remain the best source of referrals, since word of mouth outruns any directory.

    Can a willing primary care doctor learn this?

    Often, yes. A primary care doctor, or any prescriber willing to read, can be oriented with the Maudsley Deprescribing Guidelines and Chapter II of the Ashton Manual, and many doctors who would resist a patient’s preference will accept a method in a textbook.

    None of this is a reason to taper on your own. The FDA label update warns that stopping a benzodiazepine abruptly or reducing it too quickly can cause withdrawal reactions including seizures, and a slow taper still needs someone to write the prescriptions and watch the course. Unfortunately, some people who have been dismissed repeatedly decide the clinical system is not worth another try. A doctor who will not adapt has taught you something about that doctor, not that you should proceed without one.

    What does a good first visit look like?

    Bring one page: each drug, the dose, how long you have taken it, every prior attempt to taper or stop and what happened, and where you are now. A clinician who reads it carefully and asks how your symptoms move with your doses has shown you the framework in action. If a diagnosis of functional neurological disorder or health anxiety sits in your record, bring that too, with a timeline of symptoms against dose changes.

    You will usually know inside the hour. The doctor describes an approach that includes slowing down when you need to, says the symptoms are real even where the mechanism is uncertain, and does not promise a date for full recovery, because no honest clinician can. Chapter III of the Ashton Manual puts it well: a steady decline in symptoms almost invariably continues after withdrawal, though it can take a long time.

    One pattern, drawn from many such visits rather than any single patient, shows what that looks like. A person arrives with a diagnosis of health anxiety, a folder of normal test results, and a symptom log that spikes two days after every dose cut. The clinician who reads the log against the dates has already answered the question the folder could not, and the rest of the visit is spent planning rather than persuading.

    Keep looking.

    The search often takes more than one attempt, and two or three screening visits with the wrong clinician cost less than a year with one who cannot do the work. That population is small, but it is growing, partly because patients keep bringing the manuals to the appointment.

    Fortunately, the first visit gives you most of the answer. Hand the page across the desk, and watch what the doctor does with it.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

  • Tolerance Withdrawal, or Why Benzo Symptoms Can Begin Before the Taper Does

    Tolerance Withdrawal, or Why Benzo Symptoms Can Begin Before the Taper Does

    Can you be in benzodiazepine withdrawal while taking every dose on time?

    Yes, and it is easy for a prescriber to miss. A person who has taken a benzodiazepine for years, at the same dose, can slide into withdrawal without missing a pill. Chapter I of the Ashton Manual, in its section on tolerance, describes withdrawal symptoms emerging even in the continued presence of the drug, and patient communities call the state tolerance withdrawal.

    Withdrawal is supposed to happen when a drug is taken away, and here the drug is still being taken. Yet, the symptoms are real, they are new, and they are usually answered with more of the medication that is producing them. So, what does tolerance withdrawal look like from the inside, why does an office visit miss it, and what changes once it has a name?

    Tolerance is the brain adjusting to a drug that is always there.

    Benzodiazepines work by strengthening the brain’s main calming signal, a chemical called gamma-aminobutyric acid, or GABA. When that signal is boosted every day for months or years, the brain adjusts by turning its own calming machinery down. In plain terms, the brakes weaken, and the dose that once produced calm now holds the line at best.

    That adjustment is physical dependence, and physical dependence is not addiction. Nobody here has misused anything, and a brain that has adapted to a prescribed medication has a medical condition, treated with a gradual taper rather than a program.

    The Ashton Manual puts the consequence plainly. The original dose has progressively less effect, anxiety often increases over the years despite continuous use, and panic attacks and agoraphobia may appear for the first time after years of taking the drug.

    The first clue is that the symptoms are new.

    Tolerance withdrawal is routinely mistaken for the original condition getting worse, so ask whether these symptoms were ever part of it. A person who started a benzodiazepine for panic attacks a decade ago and now has numbness around the mouth, tingling in the hands and feet, muscle twitching, an inner tremor, ringing in the ears, and a stomach that rejects ordinary food had none of that at the start. While anxiety is a plausible explanation for some of it, it is an implausible explanation for all of it at once.

    Sensory and autonomic features are the ones most often reported as new: light too bright, sound too loud, a startle at ordinary noises, swings in temperature, and a heart that races without a reason. A common pattern in clinic is a person told, visit after visit, that their anxiety is progressing, when the anxiety they came in with was a fear of flying and what they have now is a fear of the supermarket lights.

    The second clue is that the symptoms keep time with the clock.

    On shorter-acting benzodiazepines such as alprazolam (Xanax) and lorazepam (Ativan), the blood level peaks and dips between doses, and Chapter II of the Ashton Manual, in its section on switching to a long-acting benzodiazepine, notes that many people experience a mini-withdrawal between each dose. In clinical experience, mornings can be the low point for the same reason, with agitation or a pounding heart that lifts an hour or two after the first dose.

    The third clue is that a higher dose stops holding.

    Dose increases stop holding: relief often lasts only a few weeks, and the symptoms return at the new dose. While this is not a perfect comparison, it is a little like a furnace running on one setting in a house that is slowly growing drafty: turning the dial up warms the rooms for a while, and then the drafts catch up. Look at the drafts, meaning the adaptation, rather than at the dial.

    Some of these symptoms are not withdrawal until a doctor has checked.

    Tolerance withdrawal is a pattern, and patterns can be imitated by a thyroid or rhythm problem, a vitamin deficiency, a nerve problem, or a medication started in the same window. Fortunately, most of what tolerance withdrawal produces is miserable rather than dangerous, and a few ordinary tests usually rule out the imitators.

    Some symptoms should never be filed under withdrawal on your own. Chest pain or pressure, a racing heart with fainting, a first-ever seizure, a sudden loss of vision or hearing, weakness on one side of the body, new confusion, or a severe headache unlike any before need to be checked the same day, and if any of them is happening now, call 911 or go to the nearest emergency department. If you are having thoughts of harming yourself, call or text 988, the Suicide and Crisis Lifeline, now.

    Why does a short visit miss it?

    Unfortunately, the standard office visit is built to miss it. A patient on a long-term benzodiazepine says they feel more anxious, the visit has fifteen minutes in it, and the question that fits is whether the anxiety is worse, not whether it has changed shape. The pen is moving toward a higher dose before the tingling and the ringing ears have been mentioned.

    There is an honest difficulty underneath the hurried one. Tolerance withdrawal and a genuine worsening of an anxiety disorder overlap, and we cannot measure a brain’s adaptation to a drug in an office. So, the distinction has to be made from the history, and the history is something only you can supply.

    A higher dose or a second drug is the usual reflex, and the wrong one.

    In medicine, we are trained to answer a worsening symptom by adding to the treatment, and the training serves well right up until the treatment is the cause. The brain adapts to a higher dose the way it adapted to the old one, and the ladder gains a rung. A second drug instead, most often a selective serotonin reuptake inhibitor, or SSRI, or a sedating medication for sleep, leaves the adaptation untouched and adds a medication that can carry its own dependence and withdrawal.

    In fact, the reflex comes from the wish to relieve suffering, and in this one situation it points the wrong way. Dr. Leeds’ view is that recognizing tolerance changes the conversation from how much more to add to how to unwind what is already there, safely and slowly. Nothing in that conversation involves stopping suddenly, since the 2020 United States Food and Drug Administration (FDA) benzodiazepine label update warns that stopping abruptly, or reducing the dose too quickly, can bring on withdrawal reactions, including seizures, which can be life-threatening.

    What does tolerance withdrawal change about the taper?

    It changes the starting line. A person who is already in withdrawal experiences the first reductions on top of a baseline that already contains withdrawal, which is why the first stretch of a taper is often planned very slowly, sometimes after a hold.

    Some patients report feeling steadier during the first weeks of a well-planned taper, which may reflect the end of dose increases and irregular timing. Clinicians who taper benzodiazepines see this often enough to mention it, but it is clinical experience, it varies, and no one should be told to expect it.

    Timing can matter as much as amount. Spreading doses evenly across the day softens the dips that drive interdose symptoms, as the article on why a hold can feel worse than a cut explains.

    For shorter-acting drugs, the Ashton Manual’s approach is a crossover taper to a longer-acting benzodiazepine, usually diazepam (Valium), chosen for its slow, smooth fall in blood level. The Maudsley Deprescribing Guidelines treat that switch as one tool among several rather than a universal step, and which path fits is a decision for you and your doctor.

    What should you bring to the visit?

    A dated timeline of symptoms is the most useful thing you can bring. Write down when each symptom first appeared, what the dose was at the time, and whether it comes and goes with the clock. Handwritten is fine, and a page of dates does more than an hour of description.

    Bring a dose history as well: which drug, how much, how often, and every increase over the years with a rough date. Saying that these symptoms are new since the medication and follow the dosing schedule asks a different question than saying your anxiety is worse, and most doctors will engage with it.

    Of course, a doctor may hesitate. You may raise it anyway, and ask whether a gradual taper, planned together, is worth discussing. The doctor must work out the pace with you, and one who has seen the timeline usually has an easier time saying yes.

    Naming it early changes what the taper is doing from the first day.

    In clinical experience, tolerance withdrawal is not rare, and it is often the first chapter of a story that ends, years later, in protracted withdrawal. That is an observation from practice, which varies, and not a rule.

    A person who recognizes it early begins the taper knowing what the symptoms are, and that knowledge takes much of the fear out of the process. If dependence, tolerance, and toxicity are still tangled, the article on the difference between the three sorts them out.

    The brain that adapted to the drug can adapt again in the other direction, on its own slow schedule, which no one can hurry. What you can do this week is start the timeline, and bring it to your next visit.

    This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.